Advaxis, Incorporated


Based in North Brunswick, New Jersey, Advaxis is developing proprietary Listeria monocytogenes (Lm) cancer vaccines based on technology developed by Dr. Yvonne Paterson, professor of microbiology at the University of Pennsylvania and chairperson of Advaxis’ scientific advisory board. Advaxis is developing attenuated live Lm vaccines that deliver engineered tumor antigens, which stimulate multiple simultaneous immunological mechanisms to fight cancer.

Saturday, March 13, 2010

Quick Finacial Data

Advaxis Inc. Form 10k Filed 2010-02-19 link - http://secwatch.com/filings/view.jsp?formid=7039487&source=api

Income Statement Snapshot


View: Annual Data | Quarterly DataAll numbers in thousands
PERIOD ENDING31-Oct-0931-Oct-0831-Oct-07
Total Revenue30 66 154
Cost of Revenue - - -
Gross Profit30 66 154
Operating Expenses
Research Development2,316 2,482 2,128
Selling General and Administrative2,701 3,036 2,629
Non Recurring - - -
Others - - -
Total Operating Expenses - - -
Operating Income or Loss(4,987)(5,452)(4,603)
Income from Continuing Operations
Total Other Income/Expenses Net5,845 47 2,756
Earnings Before Interest And Taxes858 (5,405)(1,847)
Interest Expense851 11 607
Income Before Tax7 (5,416)(2,454)
Income Tax Expense(922) - -
Minority Interest - - -
Net Income From Continuing Ops929 (5,416)(2,454)
Non-recurring Events
Discontinued Operations - - -
Extraordinary Items - - -
Effect Of Accounting Changes - - -
Other Items - - -
Net Income929 (5,416)(2,454)
Preferred Stock And Other Adjustments - - -
Net Income Applicable To Common Shares$929 ($5,416)($2,454)